Impact of noncoding <scp>RNAs</scp> on cancer directed immune therapies: Now then and forever

Roy, Roshan Kumar; Yadav, Rakhi; Sharma, Uttam; Wasson, Mishi Kaushal; Sharma, Ashok; Tanwar, Pranay; Jain, Aklank; Prakash, Hridayesh

doi:10.1002/ijc.34060

Cited by 10 publications

(3 citation statements)

References 163 publications

(261 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a type of non-coding RNAs, piRNAs have also been found to play a role in immune modulation and response to cancer. 87 It has been suggested that piRNAs can potentially influence immune cell differentiation, response to inflammation, and even affect tumor immunogenicity. 88,89 Moreover, compared to miRNAs and siRNAs, piRNAs may also potentially possess more advantages (Figure 1), for instance: a.…”

Section: Pirnasmentioning

confidence: 99%

Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy

Han,

Rao,

Zhou

et al. 2024

IJN

View full text Add to dashboard Cite

The utilization of PD-1/PD-L1 inhibitors marks a significant advancement in cancer therapy. However, the efficacy of monotherapy is still disappointing in a substantial subset of patients, necessitating the exploration of combinational strategies. Emerging from the promising results of the KEYNOTE-942 trial, RNA-based therapies, particularly circRNAs and piRNAs, have distinguished themselves as innovative sensitizers to immune checkpoint inhibitors (ICIs). These non-coding RNAs, notable for their stability and specificity, were once underrecognized but are now known for their crucial roles in regulating PD-L1 expression and bolstering anti-cancer immunity. Our manuscript offers a comprehensive analysis of selected circRNAs and piRNAs, elucidating their immunomodulatory effects and mechanisms, thus underscoring their potential as ICIs enhancers. In conjunction with the recent Nobel Prize-awarded advancements in mRNA vaccine technology, our review highlights the transformative implications of these findings for cancer treatment. We also discuss the prospects of circRNAs and piRNAs in future therapeutic applications and research. This study pioneers the synergistic application of circRNAs and piRNAs as novel sensitizers to augment PD-1/PD-L1 inhibition therapy, demonstrating their unique roles in regulating PD-L1 expression and modulating immune responses. Our findings offer a groundbreaking approach for enhancing the efficacy of cancer immunotherapy, opening new avenues for treatment strategies. This abstract aims to encapsulate the essence of our research and the burgeoning role of these non-coding RNAs in enhancing PD-1/ PD-L1 inhibition therapy, encouraging further investigation into this promising field.

show abstract

Section: Pirnasmentioning

confidence: 99%

Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy

Han,

Rao,

Zhou

et al. 2024

IJN

View full text Add to dashboard Cite

show abstract

“…Recently, immunotherapy has emerged as a potential addition to this standard regimen. This development underscores the need to understand and investigate lncRNAs as they regulate the expression of immunogenic proteins or tumor-associated antigens [ 172 ]. This regulation could stimulate an anti-tumor immune response, enhancing the effectiveness of current immunotherapies.…”

Section: Exploring Strategies For Manipulating Lncrnas To Enhance Ant...mentioning

confidence: 99%

Long Non-Coding RNAs in Colorectal Cancer: Navigating the Intersections of Immunity, Intercellular Communication, and Therapeutic Potential

Shakhpazyan,

Mikhaleva,

Bedzhanyan

et al. 2023

Biomedicines

View full text Add to dashboard Cite

This comprehensive review elucidates the intricate roles of long non-coding RNAs (lncRNAs) within the colorectal cancer (CRC) microenvironment, intersecting the domains of immunity, intercellular communication, and therapeutic potential. lncRNAs, which are significantly involved in the pathogenesis of CRC, immune evasion, and the treatment response to CRC, have crucial implications in inflammation and serve as promising candidates for novel therapeutic strategies and biomarkers. This review scrutinizes the interaction of lncRNAs with the Consensus Molecular Subtypes (CMSs) of CRC, their complex interplay with the tumor stroma affecting immunity and inflammation, and their conveyance via extracellular vesicles, particularly exosomes. Furthermore, we delve into the intricate relationship between lncRNAs and other non-coding RNAs, including microRNAs and circular RNAs, in mediating cell-to-cell communication within the CRC microenvironment. Lastly, we propose potential strategies to manipulate lncRNAs to enhance anti-tumor immunity, thereby underlining the significance of lncRNAs in devising innovative therapeutic interventions in CRC.

show abstract

“…DNA methylation, covalent modification of histones and interlinking of non-coding RNAs contribute to the cellular expression of epigenetic changes in the genome. Among the various factors involved in host epigenetic programming, non-coding RNAs (ncRNAs) such as microRNAs (miRNAs), long-stranded non-coding RNAs (lncRNAs), and cyclic RNAs, affect a various cellular processes, such as tumor immunity and cell differentiation ( Roy et al, 2022 ).…”

Section: Anti-tumor Mechanism Of Action Of the Active Ingredients Of ...mentioning

confidence: 99%

Research progress of ginseng in the treatment of gastrointestinal cancers

Song²,

Shi³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Cancer has become one of the major causes of human death. Several anticancer drugs are available; howeve their use and efficacy are limited by the toxic side effects and drug resistance caused by their continuous application. Many natural products have antitumor effects with low toxicity and fewer adverse effects. Moreover, they play an important role in enhancing the cytotoxicity of chemotherapeutic agents, reducing toxic side effects, and reversing chemoresistance. Consequently, natural drugs are being applied as potential therapeutic options in the field of antitumor treatment. As natural medicinal plants, some components of ginseng have been shown to have excellent efficacy and a good safety profile for cancer treatment. The pharmacological activities and possible mechanisms of action of ginseng have been identified. Its broad range of pharmacological activities includes antitumor, antibacterial, anti-inflammatory, antioxidant, anti-stress, anti-fibrotic, central nervous system modulating, cardioprotective, and immune-enhancing effects. Numerous studies have also shown that throuth multiple pathways, ginseng and its active ingredients exert antitumor effects on gastrointestinal (GI) tract tumors, such as esophageal, gastric, colorectal, liver, and pancreatic cancers. Herein, we introduced the main components of ginseng, including ginsenosides, polysaccharides, and sterols, etc., and reviewed the mechanism of action and research progress of ginseng in the treatment of various GI tumors. Futhermore, the pathways of action of the main components of ginseng are discussed in depth to promote the clinical development and application of ginseng in the field of anti-GI tumors.

show abstract

Impact of noncoding RNAs on cancer directed immune therapies: Now then and forever

Cited by 10 publications

References 163 publications

Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy

Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy

Long Non-Coding RNAs in Colorectal Cancer: Navigating the Intersections of Immunity, Intercellular Communication, and Therapeutic Potential

Research progress of ginseng in the treatment of gastrointestinal cancers

Contact Info

Product

Resources

About